Recruiting Ankylosing Spondylitis Studies in Hot Springs
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk f...
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study tr...
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxan...
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other pl...
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet dail...
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physi...
About Ankylosing Spondylitis Clinical Trials in Hot Springs
Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.
There are currently 6 ankylosing spondylitis clinical trials recruiting participants in Hot Springs, AR. These studies are seeking a combined 9,149 participants. Research is being sponsored by AstraZeneca, Takeda, Hoffmann-La Roche and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ankylosing Spondylitis Clinical Trials in Hot Springs — FAQ
Are there ankylosing spondylitis clinical trials in Hot Springs?
Yes, there are 6 ankylosing spondylitis clinical trials currently recruiting in Hot Springs, AR. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Hot Springs?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hot Springs research site will contact you about next steps.
Are clinical trials in Hot Springs free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hot Springs studies also compensate for your time and travel.
What ankylosing spondylitis treatments are being tested?
The 6 active trials in Hot Springs are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.
Data updated March 2, 2026 from ClinicalTrials.gov